Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.

Switching from etravirine- to doravirine-containing regimen maintains viral suppression in people with HIV-1 infection, including those with archived resistance to NNRTIs.

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...

Indian River County recorded the highest rate of new cases on the Treasure Coast, with 14 per 100,000 people diagnosed with ...